PASG Stock Price, Passage Bio Inc Quote, Chart

Market Summary

USD1.35+0.01

Delayed

0.75%

PASG Stock Price

View Fullscreen

PASG RSI Chart

PASG Valuation

Market Cap

83.2M

Price/Earnings (Trailing)

-0.99

Price/Sales (Trailing)

35.86

Price/Free Cashflow

-1.11

PASG Price/Sales (Trailing)

PASG Profitability

Return on Equity

-80.5%

Return on Assets

-60.08%

Free Cashflow Yield

-89.82%

PASG Fundamentals

PASG Revenue

Revenue (TTM)

2.3M

PASG Earnings

Earnings (TTM)

-84.4M

Earnings Growth (Yr)

51.33%

Earnings Growth (Qtr)

0.28%

Breaking Down PASG Revenue

Last 7 days

-8.2%

Last 30 days

6.3%

Last 90 days

4.7%

Trailing 12 Months

38.1%

How does PASG drawdown profile look like?

PASG Financial Health

Current Ratio

8.43

PASG Investor Care

Shares Dilution (1Y)

12.83%

Diluted EPS (TTM)

-1.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	985.0K	1.6M	2.3M
2021	0	0	0	343.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Passage Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 13, 2024	borthwick kathleen	sold	-1,425	0.97	-1,470	svp, interim cfo
Feb 13, 2024	forman mark s	sold	-1,588	0.97	-1,638	chief medical officer
Feb 10, 2024	borthwick kathleen	acquired	-	-	4,000	svp, interim cfo
Feb 10, 2024	forman mark s	acquired	-	-	5,000	chief medical officer
Jan 02, 2024	cale edgar b.	sold	-14,389	0.91	-15,813	gc & corporate secretary
Jan 02, 2024	borthwick kathleen	sold	-9,711	0.91	-10,672	svp, interim cfo
Jan 02, 2024	forman mark s	sold	-14,389	0.91	-15,813	chief medical officer
Dec 31, 2023	borthwick kathleen	acquired	-	-	30,000	svp, interim cfo
Dec 31, 2023	forman mark s	acquired	-	-	50,000	chief medical officer
Dec 31, 2023	cale edgar b.	acquired	-	-	50,000	gc & corporate secretary

Which funds bought or sold PASG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Royal Bank of Canada	added	31.93	1,000	1,000	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-28.92	-15,735	299,095	-%
May 15, 2024	STATE STREET CORP	unchanged	-	42,117	167,229	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	4,704	18,679	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-96.88	-31.00	1.00	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	5,000	18,000	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	28.00	28.00	-%
May 15, 2024	Scientech Research LLC	sold off	-100	-19,042	-	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	15,242	15,242	-%
May 15, 2024	Lynx1 Capital Management LP	added	1,178	6,158,980	6,541,930	1.70%

Are Funds Buying or Selling PASG?

Are funds buying PASG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PASG

No. of Funds

Unveiling Passage Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 12, 2024	orbimed advisors llc	13.0%	8,034,000	SC 13D/A
Mar 29, 2024	lynx1 capital management lp	8.7%	4,845,871	SC 13G
Feb 14, 2024	lynx1 capital management lp	0.7%	379,159	SC 13G/A
Nov 09, 2023	versant venture capital vi, l.p.	7.3%	4,026,417	SC 13D/A
Jun 29, 2023	orbimed advisors llc	14.7%	8,034,000	SC 13D/A
Jun 15, 2023	frazier life sciences ix, l.p.	4.7%	2,543,698	SC 13D/A
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2023	lynx1 capital management lp	5.1%	3,355,917	SC 13G/A
Sep 29, 2022	lynx1 capital management lp	5.1%	2,752,422	SC 13G
Aug 15, 2022	frazier life sciences ix, l.p.	6.9%	3,756,915	SC 13D/A

Recent SEC filings of Passage Bio Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	424B3	Prospectus Filed
May 14, 2024	8-K	Current Report
Apr 16, 2024	EFFECT	EFFECT
Apr 12, 2024	CORRESP	CORRESP
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 29, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Passage Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Passage Bio Inc News

Latest updates

Passage Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2
Revenue	42.2%	1,173,000	825,000	270,000	228,000	186,000	99,000
S&GA Expenses	-0.7%	10,587,000	10,664,000	12,991,000	17,192,000	14,978,000	15,422,000
Net Income	-1.4%	-27,071,000	-26,701,000	-39,542,000	-51,154,000	-46,915,000	-48,435,000
Net Income Margin	39.1%	-59.99	-98.47	-183	-540	-	-
Free Cashflow	-2.7%	-24,021,000	-23,395,000	-26,083,000	-30,775,000	-41,056,000	-24,330,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-6.7%	141	151	169	194	213	244	270	299	333	355	391	440	465	328	359	378	392	179	33.00
Current Assets	-8.2%	108	118	136	154	172	197	223	251	283	325	366	419	451	317	350	368	382	166	33.00
Cash Equivalents	69.4%	37.00	22.00	34.00	30.00	33.00	35.00	63.00	91.00	102	129	163	215	250	135	201	353	367	159	25.00
Net PPE	-5.3%	14.00	15.00	16.00	20.00	22.00	23.00	23.00	24.00	24.00	24.00	18.00	13.00	7.00	3.00	1.00	1.00	1.00	1.00	0.00
Liabilities	-9.2%	36.00	39.00	43.00	43.00	43.00	42.00	46.00	51.00	52.00	36.00	29.00	37.00	24.00	23.00	20.00	15.00	6.00	4.00	3.00
Current Liabilities	-21.4%	13.00	16.00	20.00	20.00	17.00	18.00	22.00	27.00	27.00	29.00	22.00	31.00	19.00	21.00	19.00	14.00	5.00	4.00	0.00
Shareholder's Equity	-5.8%	105	111	126	150	170	201	224	248	281	319	362	402	442	305	339	363	387	-	-
Retained Earnings	-2.8%	-611	-594	-577	-550	-526	-492	-465	-438	-399	-356	-305	-258	-209	-170	-131	-103	-76.20	-58.66	-13.03
Additional Paid-In Capital	1.5%	716	706	704	701	698	695	691	688	682	675	667	660	651	476	471	467	463	2.00	1.00
Shares Outstanding	12.1%	62.00	55.00	55.00	55.00	55.00	55.00	54.00	54.00	54.00	54.00	53.00	54.00	-	-	-	-	-	-	-
Float	-	-	-	-	47.00	-	-	-	101	-	-	-	483	-	-	-	772	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	3.0%	-18,929	-19,516	-19,163	-17,139	-22,446	-24,021	-23,395	-26,083	-44,711	-30,775	-41,056	-24,330	-30,718	-29,424	-17,530	-11,715	-21,851	-17,478	-11,424	-10,780	-214
Share Based Compensation	1.6%	1,595	1,570	2,824	3,743	2,784	3,477	2,862	6,278	6,337	7,575	6,815	8,561	9,740	4,324	4,033	3,855	2,368	1,036	95.00	92.00	231
Cashflow From Investing	232.3%	25,251	7,600	22,451	13,969	21,217	-3,358	-4,758	16,004	17,311	-3,605	-11,555	-10,257	-20,397	-36,546	-135,367	-94.00	-99.00	-43.00	-109	-657	-884
Cashflow From Financing	18904.3%	8,742	46.00	-	-	-	-588	-408	-406	49.00	455	44.00	523	165,634	402	44.00	-1,596	229,904	-799	109,938	46,306	20,157

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PASG Income Statement

2024-03-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 11,535	$ 16,836
General and administrative	6,515	19,047
Loss from operations	(18,050)	(35,883)
Other income (expense), net	1,339	1,545
Net loss	$ (16,711)	$ (34,338)
Per share information:
Net loss per share of common stock, basic	$ (0.30)	$ (0.63)
Net loss per share of common stock, diluted	$ (0.30)	$ (0.63)
Weighted average common shares outstanding, basic	56,295,540	54,618,799
Weighted average common shares outstanding, diluted	56,295,540	54,618,799
Comprehensive loss:
Net loss	$ (16,711)	$ (34,338)
Unrealized gain (loss) on marketable securities	(26)	539
Comprehensive loss	$ (16,737)	$ (33,799)

PASG Balance Sheet

2024-03-31

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 36,773	$ 21,709
Marketable securities	67,752	92,585
Prepaid expenses and other current assets	1,784	923
Prepaid research and development	1,984	2,742
Total current assets	108,293	117,959
Property and equipment, net	14,489	15,295
Right of use assets - operating leases	17,087	16,858
Other assets	662	433
Total assets	140,531	150,545
Current liabilities:
Accounts payable	1,687	1,298
Accrued expenses and other current liabilities	7,483	11,670
Operating lease liabilities	3,671	3,373
Total current liabilities	12,841	16,341
Operating lease liabilities - noncurrent	22,807	22,921
Total liabilities	35,648	39,262
Commitments and contingencies (note 9)
Stockholders' equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value: 300,000,000 shares authorized; 61,611,796 shares issued and outstanding at March 31, 2024 and 54,944,130 shares issued and outstanding at December 31, 2023	6	5
Additional paidin capital	716,125	705,789
Accumulated other comprehensive income (loss)	(69)	(43)
Accumulated deficit	(611,179)	(594,468)
Total stockholders' equity	104,883	111,283
Total liabilities and stockholders' equity	$ 140,531	$ 150,545

About Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ÃƒÅ¸-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CEO	Dr. William Chou M.D.
WEBSITE	passagebio.com
INDUSTRY	Biotechnology
EMPLOYEES	85

Passage Bio Inc Frequently Asked Questions

What is the ticker symbol for Passage Bio Inc? What does PASG stand for in stocks?

PASG is the stock ticker symbol of Passage Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Passage Bio Inc (PASG)?

As of Fri May 17 2024, market cap of Passage Bio Inc is 83.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PASG stock?

You can check PASG's fair value in chart for subscribers.

What is the fair value of PASG stock?

You can check PASG's fair value in chart for subscribers. The fair value of Passage Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Passage Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PASG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Passage Bio Inc a good stock to buy?

The fair value guage provides a quick view whether PASG is over valued or under valued. Whether Passage Bio Inc is cheap or expensive depends on the assumptions which impact Passage Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PASG.

What is Passage Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PASG's PE ratio (Price to Earnings) is -0.99 and Price to Sales (PS) ratio is 35.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PASG PE ratio will change depending on the future growth rate expectations of investors.